S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY ("3 + 7") FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG. (23rd June 2022) - Lübbert, M.; Wijermans, P.; Kicinski, M.; Chantepie, S.; van der Velden, W.; Noppeney, R.; Griskevicius, L.; Neubauer, A.; Crysandt, M.; Vrhovac, R.; Luppi, M.; Fuhrmann, S.; et al.